Open toolbar HOME ABOUT PRODUCTS NEWS INVESTORS CONTACT ILUVIEN® Patent Notices The following U.S. Patents cover ILUVIEN®. The absence of a U.S. Patent number as associated with ILUVIEN does not constitute a waiver of our patent, trademark, or other intellectual property rights concerning that product. Product ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg Patent No. U.S. 6,217,895 U.S. 6,375,972 U.S. 6,548,078 U.S. 8,252,307 U.S. 8,574,659 U.S. 8,871,241 Alimera Sciences is a publicly traded pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases. Facebook LinkedIn Alimera Sciences Corporate Offices 6120 Windward Parkway Suite 290 Alpharetta, GA 30005 Phone: +1 (678) 990-5740 toll-free +1 (844) 445-8843 Twitter: @alimerasciences European Website Copyright 2021 Alimera Sciences. This site intended for U.S. residents only. | Legal Statement | Privacy Policy | Privacy Shield Policy | Contact Us